导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -21.20% | 4448/4773 |
| 近一周 | -2.40% | 3822/5465 |
| 近一月 | -5.08% | 3601/5421 |
| 近一季 | -2.93% | 1520/5231 |
| 近半年 | -17.10% | 4227/4920 |
| 近一年 | -30.53% | 4227/4394 |
| 近两年 | -1.11% | 2894/2954 |
| 近三年 | -15.57% | 2093/2253 |
| 成立以来 | 7.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.17% 4354/4961 |
-16.20% 4718/5312 |
- - |
- - |
| 2025 | 1.46% 3227/4813 |
10.72% 296/3635 |
-1.08% 3105/4076 |
5.31% 3595/4524 |
-12.04% 4235/4813 |
| 2024 | 19.38% 528/3463 |
2.11% 813/2808 |
-1.30% 1031/3014 |
22.01% 513/3129 |
-2.92% 2205/3463 |
| 2023 | -14.99% 1630/2656 |
3.12% 1258/2280 |
-6.83% 1719/2385 |
-3.69% 973/2515 |
-8.12% 2251/2655 |
| 2022 | -17.14% 552/2207 |
-21.10% 1601/1919 |
19.11% 96/2016 |
-16.26% 1431/2113 |
5.30% 474/2208 |
| 2021 | -11.50% 1112/1822 |
-4.93% 896/1255 |
6.21% 761/1330 |
-13.54% 1347/1466 |
1.37% 953/1822 |
| 2020 | - - |
- - |
- - |
20.64% 51/1164 |
21.93% 50/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中金中证沪港深优选消费50指数C VS. 长安沪深300非周期A(740101) |